open access

Vol 4, No 4 (2013)
Review paper
Published online: 2014-02-06
Get Citation

Plasma cell myeloma — management recommendation of the Institute of Hematology and Transfusion Medicine

Krzysztof Jamroziak, Jarosław Czyż, Krzysztof Warzocha
Hematologia 2013;4(4):339-357.

open access

Vol 4, No 4 (2013)
REVIEW ARTICLES
Published online: 2014-02-06

Abstract

During recent years there have been significant developments in the field of diagnostics and therapy of plasma cell myeloma (PCM). Important progress regarding PCM prognosis has been a consequence of approval of new drugs, implementation of new diagnostic methods as well as optimisation of existing strategies based on results of ongoing multicentre clinical trials. However, the improvement in PCM prognosis is associated with rapidly growing costs of treatment. As a response public health service authorities in many countries including Poland have been forced to develop regulations determin­ing access to novel drugs against PCM. The PCM management recommendations of the Institute of Hematology and Transfusion Medicine (IHT) constitute a homogenous and practical diagnostic and therapeutic strategy that was developed as a compromise between newest knowledge and current administrative restrictions determining use of novel drugs in Poland. The main reason of current actualisation of the recommendations of IHT are creation of a new therapeutic programme of the Na­tional Health Found regulating treatment with bortezomib and lenalidomide in patients with PCM. These modifications have significantly changed the access to these drugs in Poland.

Abstract

During recent years there have been significant developments in the field of diagnostics and therapy of plasma cell myeloma (PCM). Important progress regarding PCM prognosis has been a consequence of approval of new drugs, implementation of new diagnostic methods as well as optimisation of existing strategies based on results of ongoing multicentre clinical trials. However, the improvement in PCM prognosis is associated with rapidly growing costs of treatment. As a response public health service authorities in many countries including Poland have been forced to develop regulations determin­ing access to novel drugs against PCM. The PCM management recommendations of the Institute of Hematology and Transfusion Medicine (IHT) constitute a homogenous and practical diagnostic and therapeutic strategy that was developed as a compromise between newest knowledge and current administrative restrictions determining use of novel drugs in Poland. The main reason of current actualisation of the recommendations of IHT are creation of a new therapeutic programme of the Na­tional Health Found regulating treatment with bortezomib and lenalidomide in patients with PCM. These modifications have significantly changed the access to these drugs in Poland.

Get Citation

Keywords

plasma cell myeloma, diagnosis, therapy, recommendations

About this article
Title

Plasma cell myeloma — management recommendation of the Institute of Hematology and Transfusion Medicine

Journal

Hematology in Clinical Practice

Issue

Vol 4, No 4 (2013)

Article type

Review paper

Pages

339-357

Published online

2014-02-06

Bibliographic record

Hematologia 2013;4(4):339-357.

Keywords

plasma cell myeloma
diagnosis
therapy
recommendations

Authors

Krzysztof Jamroziak
Jarosław Czyż
Krzysztof Warzocha

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.